• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

History of delirium tremens associated with greater mortality and morbidity risk than alcohol dependence alone

byDavy LauandAlex Chan
July 25, 2023
in Chronic Disease, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with a history of treated delirium tremens (DT) are at higher risk for all-cause mortality and alcohol-related morbidities compared to patients with just alcohol dependence (AD) or other alcohol withdrawal states (AWS), during a mean follow-up period of less than 1 year.

Evidence Rating Level: 2 (Good)

An estimated 3 to 15% of patients with alcohol use disorder (AUD) experience delirium tremens (DT), a potentially fatal form of alcohol withdrawal characterized by confusion, hallucinations, hypertension, tachycardia, and seizures. While the short-term outcomes of DT are well-studied, the long-term outcomes including mortality risk are not well-known. Therefore, this cohort study based in Norway aimed to compare the all-cause and cause-specific mortality amongst patients with DT, other alcohol withdrawal state (AWS) patients, and AUD patients with no AWS or DT. The study population consisted of adults with a diagnosis of DT, AWS, or alcohol dependence (AD) in the Norwegian Patient Registry, between 2009 and 2015. The outcomes examined included the percentage who died within the first month of the index episode and within the follow-up period, the crude annual rate of mortality, and alcohol-related morbidity. The follow-up period was from the index event until the end of 2015. In total, there were 2937 episodes of DT, 9168 episodes of AWS, and 537,742 episodes of AD, in 1816, 3993, and 30,478 patients respectively. The mean follow-up period after the index event was 36.2, 37.2, and 43.9 person-months for DT, AWS, and AD patients respectively. The study showed that DT patients had the highest mortality rate in the first month and over the duration of the follow-up period (2.5% and 24.1% respectively, p < 0.001 for both). The crude annual mortality was also highest in DT patients (8.0%) compared to AWS and AD (5.0 and 3.6% respectively). There was greater all-cause mortality risk in DT and AWS patients compared to the reference AD patients (HR 1.56, 95% CI 1.41-1.72 and HR 1.17, 95% CI 1.07-1.27 respectively). When examining causes of mortality, all patients had higher standardized mortality ratios (SMRs) for unnatural than for natural causes of death, particularly for poisoning. DT patients had significantly greater SMR than AD patients, and poisoning as the cause of death was 60 times greater in DT patients than the general population. With regards to alcohol-related morbidities, DT patients more often had admissions for alcohol-related reasons than AD patients, before and after the index event, for reasons including intoxication, pancreatitis, head injury, and liver disease. Overall, this study shows that patients who have a history of treated DT experience rates of mortality higher than patients with other alcohol use-related diagnoses.

Click to read the study in Addiction

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Combined use of cannabis and alcohol may increase driving impairment and subjective intoxication

Glucagon-like peptide-1 receptor agonists show potential in reducing substance use disorders

Limited pharmacotherapy initiation during veteran hospitalizations for alcohol use disorder

Tags: alcohol usealcohol use disorderdelirium tremenssubstance use disorder
Previous Post

Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia

Next Post

#VisualAbstract: Trial of Solanezumab in Preclinical Alzheimer’s Disease

RelatedReports

Systematic review examines benefits and adverse effects of cannabinoid therapy
Emergency

Combined use of cannabis and alcohol may increase driving impairment and subjective intoxication

May 8, 2026
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Pharma

Glucagon-like peptide-1 receptor agonists show potential in reducing substance use disorders

May 7, 2026
Increased risk of stillbirth recurrence after a previous stillbirth
Chronic Disease

Limited pharmacotherapy initiation during veteran hospitalizations for alcohol use disorder

May 4, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

May 4, 2026
Next Post
#VisualAbstract: Trial of Solanezumab in Preclinical Alzheimer’s Disease

#VisualAbstract: Trial of Solanezumab in Preclinical Alzheimer’s Disease

Antiarrhythmic drugs have no survival benefit in shock-refractory out-of-hospital cardiac arrest

Post-cardiac arrest outcomes are similar following targeted hypercapnia versus normocapnia

Parental nonmedical prescription opioid use linked to adolescent use

Early non-response is a predictor of later non-response to antipsychotics in schizophrenia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seladelpar (Livdelzi) raises the bar for primary biliary cholangitis treatment
  • Statin use after but not before breast cancer diagnosis is associated with improved mortality in hormone receptor-positive early breast cancer
  • Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.